Lundbeck to Share MSA Pipeline Data at International Congress
H. Lundbeck A/S (Lundbeck) will present key pipeline data and patient perspectives from the phase II AMULET trial, investigating amlenetug as a potential new treatment...
Category : Healthcare and Pharmaceutical
AMFM Healthcare Joins Aetna’s California Network for Mental Health
Expanded coverage brings insurance-friendly treatment options to adults and teens statewide AMFM Healthcare, a leading provider of evidence-based residential and outpatient services for mood and...
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in the randomized Phase I/II study investigating...
Liberate & Snapsheet Announce AI-Powered Claims Integration
Liberate, the leading conversational voice AI platform designed to transform the insurance industry, has announced a new partnership and pre-built integration with Snapsheet, an industry...
Marengo Doses First Patient in STARt-002 Trial for Metastatic BC
STARt-002 is a Phase 1b/2 clinical study assessing invikafusp alfa in combination with Gilead’s Trodelvy® for HR+/HER2- and TNBC breast cancer patients across leading U.S. and Canadian...
Nihon Kohden Launches Payment Solutions for Healthcare Tech
New Program Offers Flexible Financing to Make Cutting-Edge Healthcare Solutions More Accessible Nihon Kohden, a global leader in medical device innovation for high-precision patient monitoring...
Phase 3 MYR301: Bulevirtide Shows Sustained Undetectability
– 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost...
Gilead’s Livdelzi® Shows Consistent Efficacy in New EASL Data
– 60% of Participants with Prior Fibrate or Obeticholic Acid Treatment Achieve Biochemical Response with Livdelzi – – New Evidence Supports Livdelzi Delivers Clinically and...
New Inverted Light-Sheet Microscopy Platform for Research and Clinical Applications
ZEISS and Alpenglow Biosciences partner for co-development of 3D pathology solution ZEISS and Alpenglow Biosciences today announced a new partnership to jointly develop an inverted...
ENHERTU® + THP Pre-Surgery Shows Significant HER2+ Response
Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement...
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has...
Olfactive Biosolutions Gets Patent for First Effective Daily Weight Loss Pill
Pivit is a Natural Triple Receptor Agonist That Works by Increasing Three Hunger-Regulating Hormones: GLP-1, PYY and GIP Available September 2025 as a Direct-to-Consumer Supplement...
TFS HealthScience expands collaboration with Oncomatryx for OMTX705 trial
TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is deepening its collaboration with Oncomatryx, a biopharmaceutical company developing novel antibody-drug conjugates (ADCs) targeting...
Astraveus partners with NecstGen to evaluate Lakhesys for CAR-T
Astraveus SAS (“Astraveus” or the “Company”), the benchtop cell factory company, today announces that it has entered into a strategic partnership with The Netherlands Center...
Alchemab signs $415M licensing deal for ATLX-1282 with Eli Lilly
New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism Deal worth up to $415m including upfront...